Blood: The effect of anticoagulant therapy on the prognosis of thrombosis in visceral veins.

The treatment of visceral venous thrombosis (SVT) is challenging, and evidence to guide treatment decisions remains scarce.
study is a systematic review and Meta analysis designed to assess the efficacy and safety of anticoagulant therapy for SVT.
from the beginning to December 2019, MEDLINE, EMBASE, and Clinicaltrial.gov databases were searched without language restrictions to include observational studies and randomized controlled trials reporting SVT imaging or clinical outcomes.
4,312 records and eventually included a total of 7,969 patients in 97 studies.
patients receiving anticoagulant therapy, the rates of SVT recomb, SVT progression, relapse VTE, haemorrhage and total death were 58% (95% CI, 51-64), 5% (95% CI, 3-7), 11% (95% CI, 8-15), 9% (95% CI, 7-12), and 11% (95% CI, 9-14).
patients who did not have anticoagulant therapy were 22% (95% CI, 15-31), 15% (95% CI, 8-27), 14% (95% CI, 9-21), 16% (95% CI, 13-20) and 25% (95% CI, 20-31%.
anticoagulant therapy obtained a higher thrombosis rate (RR 2.39; 95% CI, 1.66-3.44) and a lower thrombosis progression rate (RR 0.24); 95% CI, 0.13-0.42), haemorrhage rate (RR 0.73; 95% CI, 0.58-0.92) and overall mortality (RR 0.45; 95% CI, 0.33-0.60).
results of this study show that anticoagulant therapy can improve SVT recombment without increasing haemorrhage, while reducing the risk of thrombosis progression.
patients treated with anticoagulants still had a high risk of relapse VTE.
were consistent with the efficacy of patients in different subgroups.
.